Murigenics
MuriGenics offers comprehensive preclinical in-vivo and in-vitro contract drug discovery and development services, supporting companies across the United States with validated protocols, statistical validation, solid science, and project management. They specialize in disease models for oncology, cardiovascular, inflammation, and metabolic diseases, aiming to deliver on-time, quality results with a focus on innovation and reliability.
Industries
Nr. of Employees
small (1-50)
Services
Non‑GLP acute, chronic, irritation, sensitization and dose‑range toxicology studies in mice and rats with clinical observations, hematology, serum chemistry and histopathology.
Rodent PK and bio‑distribution studies with plasma/tissue sampling, biliary PK and optional imaging readouts to support ADME and exposure assessments.
Efficacy studies using xenograft, syngeneic, orthotopic, homograft/GEMM and metastatic tumor models with tumor measurements, imaging and immune/readout profiling.
Adoptive cell transfer/CAR‑T evaluation, NK adoptive transfer, checkpoint inhibitor screening and immune profiling (flow cytometry, cytokines, ELISpot).
High‑throughput 96‑well assays for viability, proliferation, cytotoxicity, apoptosis, cell cycle, migration/invasion and phagocytosis using fluorescence/luminescence and imaging endpoints.
Development, validation and execution of ELISAs, bead‑based multiplex cytokine panels and ELISpot/FluoroSpot for biomarker and immune response quantification.
Non‑GLP acute, chronic, irritation, sensitization and dose‑range toxicology studies in mice and rats with clinical observations, hematology, serum chemistry and histopathology.
Rodent PK and bio‑distribution studies with plasma/tissue sampling, biliary PK and optional imaging readouts to support ADME and exposure assessments.
Efficacy studies using xenograft, syngeneic, orthotopic, homograft/GEMM and metastatic tumor models with tumor measurements, imaging and immune/readout profiling.
Adoptive cell transfer/CAR‑T evaluation, NK adoptive transfer, checkpoint inhibitor screening and immune profiling (flow cytometry, cytokines, ELISpot).
High‑throughput 96‑well assays for viability, proliferation, cytotoxicity, apoptosis, cell cycle, migration/invasion and phagocytosis using fluorescence/luminescence and imaging endpoints.
Development, validation and execution of ELISAs, bead‑based multiplex cytokine panels and ELISpot/FluoroSpot for biomarker and immune response quantification.
Expertise Areas
- Preclinical in vivo pharmacology and toxicology
- Pharmacokinetics and biodistribution
- Preclinical oncology and immuno‑oncology modeling
- In vitro cell‑based assay development and high‑throughput screening
Key Technologies
- Multicolor flow cytometry (high‑throughput)
- Bead‑based multiplex immunoassays
- ELISA and ELISpot/FluoroSpot
- qPCR and RNA sequencing sample preparation